ROP
53
-9
WYNN
36
-5
GT
56
-3
SNA
70
-5
O
17
-13
LRCX
37
-9
T
48
3
WEC
53
5
KMI
69
-2
STZ
52
-6
ADP
65
-3
AZO
50
-5
SWKS
38
-2
JNJ
41
3
KO
38
-3
DIS
85
3
INTU
58
-3
OMC
50
-16
AMZN
61
-5
NSC
53
-4
ROP
53
-9
WYNN
36
-5
GT
56
-3
SNA
70
-5
O
17
-13
LRCX
37
-9
T
48
3
WEC
53
5
KMI
69
-2
STZ
52
-6
ADP
65
-3
AZO
50
-5
SWKS
38
-2
JNJ
41
3
KO
38
-3
DIS
85
3
INTU
58
-3
OMC
50
-16
AMZN
61
-5
NSC
53
-4
Financhill
Back

Foghorn Therapeutics 10K Form

Sell
50

FHTX
Foghorn Therapeutics

Last Price:
7.67
Seasonality Move:
18.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FHTX News And Ratings

See the #1 stock for the next 7 days that we like better than FHTX

FHTX Financial Statistics

Sales & Book Value

Annual Sales: $34.16M
Cash Flow: $-21.31M
Price / Cash Flow: 0
Annual Sales: $-0.51
Price / Book: 0

Profitability

EPS (TTM): -1.92000
Net Income (TTM): $-91.22M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -30.59%

Foghorn Therapeutics Earnings Forecast

Key Foghorn Therapeutics Financial Ratios

  • The Research & Development expenses have been 321.15% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of FHTX is -288.17% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Foghorn Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FHTX
Website: foghorntx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.77
Quick Ratio: 4.71

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FHTX Technical Analysis vs Fundamental Analysis

Sell
50
Foghorn Therapeutics (FHTX) is a Sell

Is Foghorn Therapeutics a Buy or a Sell?